基本信息
views: 22
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
Dr. Tarek Hammad is the Vice President and Head of Medical Safety for Marketed Products at Takeda Pharmaceuticals. Prior to this, he held notable positions in leading pharmaceutical companies, including Sanofi and Merck KGaA, where he served as the Therapeutic Area Strategy Lead and Head of Signal Detection and Benefit-Risk Assessment, respectively. He also served as an Executive Director of Pharmacoepidemiology in US Merck.
Before transitioning to the industry, Dr. Hammad enjoyed a distinguished 13-year career at the United States FDA, where he progressively took on more responsibilities, culminating in his role as the Deputy Division Director of Pharmacoepidemiology at the Office of Surveillance and Epidemiology (OSE), CDER. He received several prestigious awards during his tenure at the FDA, including the FDA Distinguished Service Award and the Frances Kelsey Excellence in Drug Safety Award.
Throughout his career, Dr. Hammad has made substantial contributions to the scientific community through teaching, publications, as a peer reviewer for major scientific journals, and working with public-private consortia dedicated to advancing innovation in drug development (e.g., the Innovation in Medicine Initiative (IMI) and the Council for International Organizations of Medical Sciences (CIOMS)). His expertise extends to his participation in the ICH Expert Working Group (EWG M4E(R2)) on "Enhancing the Format and Structure of Benefit-Risk Information." His reputation as an expert in drug safety, pharmacoepidemiology, and benefit-risk assessment is nationally and internationally recognized.
As a sought-after speaker, Dr. Hammad is frequently invited to webinars, symposia, and scientific conferences, where he shares his insights. He has also assumed roles as a session chair and member of program committees. Alongside his professional accomplishments, Dr. Hammad has held various academic appointments and authored over 80 peer-reviewed articles, letters to the editor, and book chapters. For more information, visit www.DrTarekHammad.com.
Research Interests
Papers共 100 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Frontiers in drug safety and regulation (2023)
Frontiers in drug safety and regulation (2023)
Tomas G Neilan,Mace L Rothenberg,Laleh Amiri-Kordestani,Ryan J Sullivan,Richard M Steingart,William Gregory,Subramanian Hariharan,Tarek A Hammad,JoAnn Lindenfeld,Martin J Murphy,Javid J Moslehi, Checkpoint Inhibitor Safety Working Group
Benefit-Risk Assessment Methods in Medical Product Developmentpp.15-51, (2017)
International Journal for Population Data Scienceno. 1 (2017)
Load More
Author Statistics
#Papers: 76
#Citation: 4101
H-Index: 32
G-Index: 64
Sociability: 6
Diversity: 1
Activity: 0
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn